Oncombat
Small Cell Lung Cancer (SCLC) is a neuroendocrine cancer with a devastating low 5-year survival rate of less than 5%. Challenges to improving this situation include the difficulty in early detection of disease and the lack of effective chemotherapy. Our team has discovered a series of proprietary small peptides that selectively target human SCLC cells. Their conjugation to selected drugs creates Peptide-Drug-Conjugates (PDCs) that specifically target the drugs inside the cancer cells to block key cellular mechanisms essential for survival of SCLC tumors. This innovation will have significant impact for SCLC patients by providing a new therapy that bypasses the toxic side effects of chemotherapies and offers a realistic therapeutic option for currently unmet need.
The global market for small-cell lung cancer drugs expected to become $3.4 billion by 2027, expanding at a CAGR of 19.4% over the forecast period, driven by the approval and uptake of premium-priced targeted therapies
Our team has discovered a series of proprietary small peptides that selectively target human SCLC cells. Their conjugation to selected drugs creates Peptide-Drug-Conjugates (PDCs) that specifically target the drugs inside the cancer cells to block key cellular mechanisms essential for survival of SCLC tumors. This innovation will have significant impact for SCLC patients by providing a new therapy that bypasses the toxic side effects of chemotherapies and offers a realistic therapeutic option for currently unmet need.
Mice with SCLC flank tumors were injected with 3 mg/Kg FITC-conjugated specific or control peptides via the
lateral tail vein. Three hours post injection mice were killed and tissues fluorescence was determined by optical visualization or FACS analysis.
